C5 and paroxysmal nocturnal hemoglobinuria: On the other hand, eculizumab, which is a humanized mAb against C5 complement protein, originally used to treat paroxysmal nocturnal hemoglobinuria (PNH) is an approved treatment option for generalized AChR antibody-positive MG.